Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
7 hedge funds and large institutions have $182K invested in Therapix Biosciences Ltd. in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
40% more funds holding
Funds holding: 5 → 7 (+2)
39% less capital invested
Capital invested by funds: $298K → $182K (-$116K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$91.5K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.39K |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
+$1.39K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$626 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$91.9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$88K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$939 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $92K | +$91.5K | +13,155 | New |
|
|
2
Morgan Stanley
New York
| $79K | -$91.9K | -13,212 | -54% |
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1K | -$939 | -135 | -57% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $1K | +$626 | +90 | New |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$1.39K | +200 | New |
|
|
PA
7
Parallel Advisors
San Francisco,
California
| $1K | +$1.39K | +200 | New |
|
|
VKH
8
Virtu KCG Holdings
New York
| – | -$88K | -10,931 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$2K | -230 | Closed |
|
TRPX Hedge Fund Activity: Q2 2017 in Review
7 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q2 2017, worth a combined $182K — down 39% from $298K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRPX positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $91.5K. The largest seller was Morgan Stanley, cutting an estimated $91.9K.
- 7 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q2 2017, up from 5 in Q1 2017.
- Funds reported $182K of Therapix Biosciences Ltd. stock for Q2 2017, down 39% quarter-over-quarter.
- 4 funds opened new Therapix Biosciences Ltd. positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Therapix Biosciences Ltd. buyer in Q2 2017 was Jane Street, an estimated $91.5K added.
- The largest Therapix Biosciences Ltd. seller in Q2 2017 was Morgan Stanley, an estimated $91.9K sold.
Based on aggregated 13F filings for Q2 2017.